Qiuli Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qiuli Li has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Yin Li
Department of Otorhinolaryngology Ludwigs‐Maximilians‐University Medical Centre Munich Germany
6 shared publicationsJiahe Tian
Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060
5 shared publicationsZhongyu Wang
Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou China
5 shared publicationsAng Hu
Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou China
4 shared publicationsKe Jiang
Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou China
4 shared publications- Ankui Yang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China
2 shared publications
Latest Publications
- 25 June 2026
- Published by Wiley in Head & Neck
- Vol. 48 (12) , 3372-3383
Clinicopathological Characteristics and Prognostic Significance of RET Fusion in Papillary Thyroid Carcinoma
Background: To analyze the clinicopathological features and long‐term outcomes of papillary thyroid carcinoma (PTC) patients with rearranged during transfection (RET) proto‐oncogene fusion positive and to explore their genotype–phenotype associations and prognostic significance. Methods: A retrospective study was conducted on 828 PTC patients treated at Sun Yat‐sen University Cancer Center between January 2018 and December 2020. RET fusions, as well as BRAF and TERT promoter mutations, were primarily detected by quantitative real‐time polymerase chain reaction. Demographic, clinicopathological, and follow‐up data were obtained and analyzed to identify genotype‐specific disease patterns. Results: RET fusions were identified in 64 patients (7.7%). RET fusion‐positive patients had a significantly greater proportion of pediatric and adolescent onset (12.5% vs. 0.7%; p < 0.001) and had larger tumors (34.4% vs. 10.1%, p < 0.001), higher rates of lateral cervical lymph node metastasis (64.1% vs. 24.6%, p < 0.001), distant metastasis (14.1% vs. 1.0%, p < 0.001), extrathyroidal extension (23.4% vs. 13.9%, p = 0.037), vascular invasion (17.2% vs. 3.9%, p < 0.001), perineural invasion (17.2% vs. 4.6%, p < 0.001), and extranodal extension (34.4% vs. 4.8%, p < 0.001) than their RET fusion‐negative counterparts. The follow‐up data indicated a higher rate of disease progression and poorer clinical outcomes in RET fusion‐positive patients than in RET fusion‐negative patients (21.9% vs. 2.6%, p < 0.001). Conclusions: RET fusion‐positive PTC is associated with aggressive clinicopathological behavior and poor prognosis. This study highlights the importance of RET fusion testing in PTC for more accurate risk stratification and personalized therapeutic approaches, particularly for high‐risk patients.
- 25 June 2026
- Published by Wiley in Head & Neck
- Vol. 48 (12) , 3372-3383
Clinicopathological Characteristics and Prognostic Significance of RET Fusion in Papillary Thyroid Carcinoma
Background: To analyze the clinicopathological features and long‐term outcomes of papillary thyroid carcinoma (PTC) patients with rearranged during transfection (RET) proto‐oncogene fusion positive and to explore their genotype–phenotype associations and prognostic significance. Methods: A retrospective study was conducted on 828 PTC patients treated at Sun Yat‐sen University Cancer Center between January 2018 and December 2020. RET fusions, as well as BRAF and TERT promoter mutations, were primarily detected by quantitative real‐time polymerase chain reaction. Demographic, clinicopathological, and follow‐up data were obtained and analyzed to identify genotype‐specific disease patterns. Results: RET fusions were identified in 64 patients (7.7%). RET fusion‐positive patients had a significantly greater proportion of pediatric and adolescent onset (12.5% vs. 0.7%; p < 0.001) and had larger tumors (34.4% vs. 10.1%, p < 0.001), higher rates of lateral cervical lymph node metastasis (64.1% vs. 24.6%, p < 0.001), distant metastasis (14.1% vs. 1.0%, p < 0.001), extrathyroidal extension (23.4% vs. 13.9%, p = 0.037), vascular invasion (17.2% vs. 3.9%, p < 0.001), perineural invasion (17.2% vs. 4.6%, p < 0.001), and extranodal extension (34.4% vs. 4.8%, p < 0.001) than their RET fusion‐negative counterparts. The follow‐up data indicated a higher rate of disease progression and poorer clinical outcomes in RET fusion‐positive patients than in RET fusion‐negative patients (21.9% vs. 2.6%, p < 0.001). Conclusions: RET fusion‐positive PTC is associated with aggressive clinicopathological behavior and poor prognosis. This study highlights the importance of RET fusion testing in PTC for more accurate risk stratification and personalized therapeutic approaches, particularly for high‐risk patients.
- Open Access
- 16 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (11)
NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer
Inactivating NOTCH1 mutations in head and neck squamous cell carcinoma (HNSCC) were described over a decade ago, suggesting a tumor suppressor function — unlike its oncogenic role in other tumors. Today, much debate persists regarding a putative oncogenic role in HNSCC as well, with reports that NOTCH1 signaling drives tumor growth and a cancer stem cell (CSC) phenotype. In this work, comprehensive experiments unequivocally demonstrate that NOTCH1 is a tumor suppressor in HNSCC regardless of mutation or activation status and that it reduces CSC frequency. We developed a signature of NOTCH1 activation showing the pathway is associated with very early differentiation, an altered tumor microenvironment, and better prognosis. Clarifying whether NOTCH1 occasionally functions as an oncogenic driver in HNSCC is crucial to prognosis and personalized therapy. The results presented unify the field, reconcile conflicting data, and provide critical insights into the biological and clinical significance of NOTCH1 , with broader implications in other squamous carcinomas with NOTCH1 mutations.
- 16 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (11)
Open AccessNOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer
Inactivating NOTCH1 mutations in head and neck squamous cell carcinoma (HNSCC) were described over a decade ago, suggesting a tumor suppressor function — unlike its oncogenic role in other tumors. Today, much debate persists regarding a putative oncogenic role in HNSCC as well, with reports that NOTCH1 signaling drives tumor growth and a cancer stem cell (CSC) phenotype. In this work, comprehensive experiments unequivocally demonstrate that NOTCH1 is a tumor suppressor in HNSCC regardless of mutation or activation status and that it reduces CSC frequency. We developed a signature of NOTCH1 activation showing the pathway is associated with very early differentiation, an altered tumor microenvironment, and better prognosis. Clarifying whether NOTCH1 occasionally functions as an oncogenic driver in HNSCC is crucial to prognosis and personalized therapy. The results presented unify the field, reconcile conflicting data, and provide critical insights into the biological and clinical significance of NOTCH1 , with broader implications in other squamous carcinomas with NOTCH1 mutations.
- 11 December 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , 1232-1247
An Interpretable Machine-Learning Model for Predicting Occult Central Lymph Node Metastasis in Papillary Thyroid Cancer
Context: Accurate preoperative prediction of occult lymph node metastasis (OLNM) in clinically lymph node negative (cN0) papillary thyroid carcinoma (PTC) is critical for optimizing therapeutic strategy, particularly for thermal ablation and active surveillance. Objective: The aim of this study was to develop an interpretable machine-learning (ML) model to predict the risk of OLNM in cN0 PTC patients. Methods: This retrospective study analyzed data of 961 cN0 PTC patients (August 2018-August 2023). Multivariable logistic regression identified independent risk factors for OLNM in cN0 PTC. The cohort was randomly divided into the training and test sets, and a subset of patients with tumors sized 1 cm or less was further extracted from the test set for internal validation. Eight ML models incorporating clinical, ultrasonographic, and molecular features were developed and evaluated. Shapley Additive exPlanations (SHAP) enhanced interpretability. Results: RET fusion positivity and BRAF mutation positivity were identified as independent molecular risk factors for OLNM in cN0 PTC, alongside 6 clinical and ultrasonographic variables. Nine predictors were incorporated into the predictive model. The random forest (RF) model achieved optimal performance with an area under the curve (AUC) of 0.906 in the training set and 0.733 in the test set, along with the lowest Brier scores of 0.135 and 0.212, respectively. Analysis of tumors sized 1 cm or less internally validated the model's robustness with an AUC of 0.719. SHAP analysis identified size, age, and clustered punctate echogenic foci as the top predictors. Conclusion: This is the first study to identify RET fusion positivity as an independent OLNM risk factor in cN0 PTC. The developed RF model demonstrates moderate predictive performance for OLNM risk and provides a framework for integrating clinical, sonographic, and molecular data, and is deployed as a web calculator (https://predictingoccultlymphnodemetastasis.shinyapps.io/web3/).
- 11 December 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , 1232-1247
An Interpretable Machine-Learning Model for Predicting Occult Central Lymph Node Metastasis in Papillary Thyroid Cancer
Context: Accurate preoperative prediction of occult lymph node metastasis (OLNM) in clinically lymph node negative (cN0) papillary thyroid carcinoma (PTC) is critical for optimizing therapeutic strategy, particularly for thermal ablation and active surveillance. Objective: The aim of this study was to develop an interpretable machine-learning (ML) model to predict the risk of OLNM in cN0 PTC patients. Methods: This retrospective study analyzed data of 961 cN0 PTC patients (August 2018-August 2023). Multivariable logistic regression identified independent risk factors for OLNM in cN0 PTC. The cohort was randomly divided into the training and test sets, and a subset of patients with tumors sized 1 cm or less was further extracted from the test set for internal validation. Eight ML models incorporating clinical, ultrasonographic, and molecular features were developed and evaluated. Shapley Additive exPlanations (SHAP) enhanced interpretability. Results: RET fusion positivity and BRAF mutation positivity were identified as independent molecular risk factors for OLNM in cN0 PTC, alongside 6 clinical and ultrasonographic variables. Nine predictors were incorporated into the predictive model. The random forest (RF) model achieved optimal performance with an area under the curve (AUC) of 0.906 in the training set and 0.733 in the test set, along with the lowest Brier scores of 0.135 and 0.212, respectively. Analysis of tumors sized 1 cm or less internally validated the model's robustness with an AUC of 0.719. SHAP analysis identified size, age, and clustered punctate echogenic foci as the top predictors. Conclusion: This is the first study to identify RET fusion positivity as an independent OLNM risk factor in cN0 PTC. The developed RF model demonstrates moderate predictive performance for OLNM risk and provides a framework for integrating clinical, sonographic, and molecular data, and is deployed as a web calculator (https://predictingoccultlymphnodemetastasis.shinyapps.io/web3/).
- 3 July 2025
- Published by Elsevier in Oral Oncology
- Vol. 167, 107464
RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma
- 3 July 2025
- Published by Elsevier in Oral Oncology
- Vol. 167, 107464
RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma
- Open Access
- 30 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Author Correction: Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils
- 30 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Open AccessAuthor Correction: Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils
- Open Access
- 28 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils
Relatlimab and nivolumab combination therapy shows significant efficacy in treating various types of cancer. Current research on the molecular mechanisms of this treatment is abundant, but in-depth investigations into post-treatment resistance remain notably lacking. In this study, we identify significant enrichment of SRY (sex determining region Y)-box 9 (Sox9)+ tumor cells in resistant samples using single cell RNA sequencing (scRNAseq) in a head and neck squamous cell carcinoma (HNSCC) mouse model. In addition, Sox9 directly regulates the expression of annexin A1 (Anxa1), mediating apoptosis of formyl peptide receptor 1 (Fpr1)+ neutrophils through the Anxa1-Fpr1 axis, which promotes mitochondrial fission, inhibits mitophagy by downregulating BCL2/adenovirus E1B interacting protein 3 (Bnip3) expression and ultimately prevents the accumulation of neutrophils in tumor tissues. The reduction of Fpr1+ neutrophils impairs the infiltration and tumor cell-killing ability of cytotoxic Cd8 T and γδT cells within the tumor microenvironment, thereby leading to the development of resistance to the combination therapy. We further validate these findings using various transgenic mouse models. Overall, this study comprehensively explains the mechanisms underlying resistance to the anti-LAG-3 plus anti-PD-1 combination therapy and identifies potential therapeutic targets to overcome this resistance.
- 28 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Open AccessResistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils
Relatlimab and nivolumab combination therapy shows significant efficacy in treating various types of cancer. Current research on the molecular mechanisms of this treatment is abundant, but in-depth investigations into post-treatment resistance remain notably lacking. In this study, we identify significant enrichment of SRY (sex determining region Y)-box 9 (Sox9)+ tumor cells in resistant samples using single cell RNA sequencing (scRNAseq) in a head and neck squamous cell carcinoma (HNSCC) mouse model. In addition, Sox9 directly regulates the expression of annexin A1 (Anxa1), mediating apoptosis of formyl peptide receptor 1 (Fpr1)+ neutrophils through the Anxa1-Fpr1 axis, which promotes mitochondrial fission, inhibits mitophagy by downregulating BCL2/adenovirus E1B interacting protein 3 (Bnip3) expression and ultimately prevents the accumulation of neutrophils in tumor tissues. The reduction of Fpr1+ neutrophils impairs the infiltration and tumor cell-killing ability of cytotoxic Cd8 T and γδT cells within the tumor microenvironment, thereby leading to the development of resistance to the combination therapy. We further validate these findings using various transgenic mouse models. Overall, this study comprehensively explains the mechanisms underlying resistance to the anti-LAG-3 plus anti-PD-1 combination therapy and identifies potential therapeutic targets to overcome this resistance.
- 3 February 2025
- Published by Springer Nature in Endocrine
- Vol. 88 (2) , 511-522
Analysis of prognostic factors and establishment of a recurrence risk prediction model for papillary thyroid carcinoma based on BRAF stratification
Background Predicting the likelihood of papillary thyroid carcinoma (PTC) recurrence is crucial for improving patient outcomes. The association between the BRAF V600E (BRAF) mutation and PTC recurrence remains controversial. Our goal was to determine prognostic features of PTC patients and construct models for predicting recurrence risk according to BRAF mutation status. Methods A total of 811 PTC patients whose clinical information and survival data were available were included in this study. Independent prognostic variables of PTC identified by screening via LASSO-Cox regression analysis were then used to construct nomograms. The performance of the predictive models was assessed according to the C-index, ROC curve, validation curve, and decision curve analyses. Kaplan–Meier curves were used to analyze differences between patients grouped according to prognostic factors and relapse risk. Results Multivariate Cox regression analysis demonstrated that extrathyroidal extension (ETE), vascular tumor thrombus, and lymph node yield (LNY) were correlated with recurrence-free survival (RFS) in the BRAF mutation-negative group, while extranodal extension (ENE), number of metastatic lymph node (NMLN), pathological stage, and vascular tumor thrombus were correlated with RFS in the BRAF mutation-positive group. The mutation-stratified predictive models demonstrated better performance than the model without stratification, as indicated by the greater C-index values (0.880 vs. 0.859 vs. 0.753), AUC values (1-year AUC: 0.946 vs. 0.947 vs. 0.758; 3-year AUC: 0.889 vs. 0.871 vs. 0.760; 5-year AUC: 0.845 vs. 0.793 vs. 0.758), and net clinical benefit. The calibration curves at 1 year, 3 years, and 5 years showed good consistency. The bootstrap internal validation had good AUC values exceeding 0.8 and showed a well-fitting calibration curve. Significant differences in RFS were observed between the low-risk and high-risk groups (P < 0.001). Conclusion Stratifying patients based on their BRAF mutation status can facilitate the development of better and more targeted postoperative management strategies. Nomograms for BRAF mutation positive and negative patients were developed to precisely and consistently predict recurrence risk in PTC patients.
- 3 February 2025
- Published by Springer Nature in Endocrine
- Vol. 88 (2) , 511-522
Analysis of prognostic factors and establishment of a recurrence risk prediction model for papillary thyroid carcinoma based on BRAF stratification
Background Predicting the likelihood of papillary thyroid carcinoma (PTC) recurrence is crucial for improving patient outcomes. The association between the BRAF V600E (BRAF) mutation and PTC recurrence remains controversial. Our goal was to determine prognostic features of PTC patients and construct models for predicting recurrence risk according to BRAF mutation status. Methods A total of 811 PTC patients whose clinical information and survival data were available were included in this study. Independent prognostic variables of PTC identified by screening via LASSO-Cox regression analysis were then used to construct nomograms. The performance of the predictive models was assessed according to the C-index, ROC curve, validation curve, and decision curve analyses. Kaplan–Meier curves were used to analyze differences between patients grouped according to prognostic factors and relapse risk. Results Multivariate Cox regression analysis demonstrated that extrathyroidal extension (ETE), vascular tumor thrombus, and lymph node yield (LNY) were correlated with recurrence-free survival (RFS) in the BRAF mutation-negative group, while extranodal extension (ENE), number of metastatic lymph node (NMLN), pathological stage, and vascular tumor thrombus were correlated with RFS in the BRAF mutation-positive group. The mutation-stratified predictive models demonstrated better performance than the model without stratification, as indicated by the greater C-index values (0.880 vs. 0.859 vs. 0.753), AUC values (1-year AUC: 0.946 vs. 0.947 vs. 0.758; 3-year AUC: 0.889 vs. 0.871 vs. 0.760; 5-year AUC: 0.845 vs. 0.793 vs. 0.758), and net clinical benefit. The calibration curves at 1 year, 3 years, and 5 years showed good consistency. The bootstrap internal validation had good AUC values exceeding 0.8 and showed a well-fitting calibration curve. Significant differences in RFS were observed between the low-risk and high-risk groups (P < 0.001). Conclusion Stratifying patients based on their BRAF mutation status can facilitate the development of better and more targeted postoperative management strategies. Nomograms for BRAF mutation positive and negative patients were developed to precisely and consistently predict recurrence risk in PTC patients.
- Open Access
- 14 November 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1484838
The diagnosis and management of small and indeterminate lymph nodes in papillary thyroid cancer: preoperatively and intraoperatively
Although thyroid cancer is an indolent tumor with a favorable prognosis, lymph node metastasis (LNM) serves as a major concern for many patients. Because LNM is strongly correlated with recurrence, distant metastasis, and shortened survival, a precise and timely diagnosis and following appropriate management for LNM are necessary. However, significant challenges still exist in the diagnosis of small LNs (<1 cm in diameter), and their low volume makes it difficult to determine whether they are metastatic or benign. Therefore, the diagnostic technique for these small and indeterminate LNs (siLNs) has been one of the leading research subjects in recent years. The implementation of innovative technologies, such as contrast-enhanced ultrasonography, frozen section, and molecular detection, has brought great progress to the diagnosis of siLNs. Meanwhile, the strategies for managing siLNs in clinical practice have evolved considerably over the past several years, with several appropriate options recommended by guidelines. In this review, we aim to provide a systematic overview of the latest studies and potential evidence about effective approaches for detecting and evaluating siLNs. Furthermore, the following management modalities of siLNs in different situations are well discussed.
- 14 November 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1484838
Open AccessThe diagnosis and management of small and indeterminate lymph nodes in papillary thyroid cancer: preoperatively and intraoperatively
Although thyroid cancer is an indolent tumor with a favorable prognosis, lymph node metastasis (LNM) serves as a major concern for many patients. Because LNM is strongly correlated with recurrence, distant metastasis, and shortened survival, a precise and timely diagnosis and following appropriate management for LNM are necessary. However, significant challenges still exist in the diagnosis of small LNs (<1 cm in diameter), and their low volume makes it difficult to determine whether they are metastatic or benign. Therefore, the diagnostic technique for these small and indeterminate LNs (siLNs) has been one of the leading research subjects in recent years. The implementation of innovative technologies, such as contrast-enhanced ultrasonography, frozen section, and molecular detection, has brought great progress to the diagnosis of siLNs. Meanwhile, the strategies for managing siLNs in clinical practice have evolved considerably over the past several years, with several appropriate options recommended by guidelines. In this review, we aim to provide a systematic overview of the latest studies and potential evidence about effective approaches for detecting and evaluating siLNs. Furthermore, the following management modalities of siLNs in different situations are well discussed.
- 27 November 2023
- Published by Elsevier in Cellular Signalling
- Vol. 114, 110984
A prognostic model based on Scissor+ cancer associated fibroblasts identified from bulk and single cell RNA sequencing data in head and neck squamous cell carcinoma
- 27 November 2023
- Published by Elsevier in Cellular Signalling
- Vol. 114, 110984
A prognostic model based on Scissor+ cancer associated fibroblasts identified from bulk and single cell RNA sequencing data in head and neck squamous cell carcinoma
- Open Access
- 21 September 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1268282
Risk factors and predictive model for recurrence in papillary thyroid carcinoma: a single-center retrospective cohort study based on 955 cases
Background: The 2015 American Thyroid Association guidelines proposed recurrence risk stratification of differentiated thyroid carcinoma, including papillary thyroid carcinoma (PTC), but this stratification excluded non–initial treatment patients with worse outcomes. This study aimed to explore the potential risk factors for recurrence in PTC and develop a predictive model for both initial and non–initial treatment of patients with PTC.Methods: A total of 955 patients were included in this study. Differences between the recurrence (−) and recurrence (+) groups were compared. The 955 patients were randomized into two groups: the training group (671 cases) and the validation group (284 cases). All variables were selected using the LASSO regression analysis. A nomogram was developed based on the results of the univariate and multivariate logistic regression analyses. The nomogram performance was evaluated using discrimination and calibration.Results: Patients aged ≥55 years, extranodal extension (ENE), metastatic LN ratio (LNR) >0.5, and non–initial treatment were identified as potential risk factors for recurrence through LASSO regression and univariate and multivariate analyses. The receiver operating characteristic curve (ROC curve) showed high efficiency, with an area under the ROC curve (AUC) of 0.819 (95% confidence interval [CI], 0.729–0.909) and 0.818 (95% CI, 0.670–0.909) in the training and validation groups, respectively. The calibration curve indicated that the nomogram had a good consistency.Conclusion: In patients with PTC, age ≥55 years, ENE, LNR >0.5, and non–initial treatment are potential risk factors for recurrence. The predictive model of recurrence was confirmed to be a practical and convenient tool for clinicians to accurately predict PTC recurrence.
- 21 September 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1268282
Open AccessRisk factors and predictive model for recurrence in papillary thyroid carcinoma: a single-center retrospective cohort study based on 955 cases
Background: The 2015 American Thyroid Association guidelines proposed recurrence risk stratification of differentiated thyroid carcinoma, including papillary thyroid carcinoma (PTC), but this stratification excluded non–initial treatment patients with worse outcomes. This study aimed to explore the potential risk factors for recurrence in PTC and develop a predictive model for both initial and non–initial treatment of patients with PTC.Methods: A total of 955 patients were included in this study. Differences between the recurrence (−) and recurrence (+) groups were compared. The 955 patients were randomized into two groups: the training group (671 cases) and the validation group (284 cases). All variables were selected using the LASSO regression analysis. A nomogram was developed based on the results of the univariate and multivariate logistic regression analyses. The nomogram performance was evaluated using discrimination and calibration.Results: Patients aged ≥55 years, extranodal extension (ENE), metastatic LN ratio (LNR) >0.5, and non–initial treatment were identified as potential risk factors for recurrence through LASSO regression and univariate and multivariate analyses. The receiver operating characteristic curve (ROC curve) showed high efficiency, with an area under the ROC curve (AUC) of 0.819 (95% confidence interval [CI], 0.729–0.909) and 0.818 (95% CI, 0.670–0.909) in the training and validation groups, respectively. The calibration curve indicated that the nomogram had a good consistency.Conclusion: In patients with PTC, age ≥55 years, ENE, LNR >0.5, and non–initial treatment are potential risk factors for recurrence. The predictive model of recurrence was confirmed to be a practical and convenient tool for clinicians to accurately predict PTC recurrence.